Guardant Health
6 known investors
Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
Investors · 6
In the news
- Guggenheim raises Guardant Health stock price target on Shield data By Investing.cominvesting.com · 2026
- TD Cowen raises Guardant Health stock price target on FDA approval By Investing.cominvesting.com · 2026
- Guardant Health stock surges on colon cancer blood test news - TheStreetthestreet.com · 2026
- Guardant Health (GH) Sees Share Price Surge Following UnitedHealth Coverage Announcementgurufocus.com · 2026
- Guardant Health (GH) Stock After 193% One-Year Gain Is The Rally Running Out Of Room - Simply Wall St Newssimplywall.st · 2026
- Guardant Health stock climbs as investors continue to digest screening and diagnostics catalysts | Quiver Quantitativequiverquant.com · 2026